
Carmat S.A (ALCAR) | Financial Analysis & Statements
Carmat S.A. | Small-cap | Healthcare
Carmat S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
42.4M
Total Liabilities
93.6M
Shareholders Equity
-51.1M
Cash Flow Metrics
Revenue & Profitability Trend
Carmat S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 7.0M | 2.8M | 372.0K | 2.3M | 0 |
Cost of Goods Sold | 30.6M | 33.8M | 28.8M | 42.8M | 24.4M |
Gross Profit | -23.6M | -31.0M | -28.4M | -40.5M | -24.4M |
Gross Margin % | -336.6% | -1,087.5% | -7,647.0% | -1,732.7% | 0.0% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | - | - |
Other Operating Expenses | 6.6M | 2.4M | 4.8M | 2.9M | 794.0K |
Total Operating Expenses | 6.6M | 2.4M | 4.8M | 2.9M | 794.0K |
Operating Income | -40.1M | -41.0M | -44.1M | -48.1M | -28.9M |
Operating Margin % | -573.0% | -1,438.7% | -11,864.5% | -2,058.5% | 0.0% |
Non-Operating Items | |||||
Interest Income | 121.0K | 373.0K | - | - | - |
Interest Expense | 3.3M | 3.4M | 3.8M | 3.3M | 2.5M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -53.1M | -55.6M | -55.7M | -63.7M | -38.7M |
Income Tax | -1.7M | -1.7M | -2.1M | -1.9M | -1.7M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -51.4M | -53.9M | -53.7M | -61.9M | -37.0M |
Net Margin % | -734.2% | -1,891.4% | -14,430.1% | -2,646.4% | 0.0% |
Key Metrics | |||||
EBITDA | -39.8M | -34.7M | -45.6M | -39.7M | -20.6M |
EPS (Basic) | €-1.15 | €-2.09 | €-2.28 | €-3.97 | €-2.85 |
EPS (Diluted) | €-1.15 | €-2.09 | €-2.28 | €-3.97 | €-2.85 |
Basic Shares Outstanding | 44691304 | 25815625 | 23595340 | 15585139 | 12969474 |
Diluted Shares Outstanding | 44691304 | 25815625 | 23595340 | 15585139 | 12969474 |
Income Statement Trend
Carmat S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 4.7M | 8.0M | 51.4M | 39.2M | 36.0M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.5M | 1.3M | 140.0K | 464.0K | - |
Inventory | 19.8M | 23.9M | 17.4M | 14.3M | 9.9M |
Other Current Assets | 1.0K | -1.0K | -1.0K | 1.0K | 1.0K |
Total Current Assets | 32.4M | 42.4M | 77.8M | 61.7M | 52.9M |
Non-Current Assets | |||||
Property, Plant & Equipment | 21.3M | 6.2M | 5.2M | 5.4M | 3.8M |
Goodwill | 73.0K | 72.0K | 0 | 88.0K | 17.0K |
Intangible Assets | 73.0K | 72.0K | - | 88.0K | 17.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 12.0K | 38.0K | 37.0K | 8.0K | - |
Total Non-Current Assets | 10.1M | 10.7M | 7.5M | 7.4M | 7.0M |
Total Assets | 42.4M | 53.1M | 85.2M | 69.1M | 59.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 5.2M | 9.6M | 6.5M | 8.4M | 8.0M |
Short-term Debt | 2.3M | - | 2.6M | 133.0K | 79.4K |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 4.3M | 4.9M | - | - | 14.5M |
Total Current Liabilities | 19.1M | 20.4M | 12.2M | 13.6M | 12.4M |
Non-Current Liabilities | |||||
Long-term Debt | 55.5M | 57.6M | 55.4M | 52.0M | 38.9M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 16.8M | 16.8M | 14.5M | 14.5M | 14.5M |
Total Non-Current Liabilities | 74.5M | 76.4M | 71.0M | 69.1M | 54.1M |
Total Liabilities | 93.6M | 96.8M | 83.3M | 82.6M | 66.5M |
Equity | |||||
Common Stock | 1.8M | 992.0K | 907.0K | 623.0K | 520.0K |
Retained Earnings | -98.5M | -55.1M | -68.9M | -98.8M | -37.0M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | -51.1M | -43.8M | 2.0M | -13.5M | -6.7M |
Key Metrics | |||||
Total Debt | 57.8M | 57.6M | 58.0M | 52.2M | 39.0M |
Working Capital | 13.3M | 22.0M | 65.5M | 48.1M | 40.4M |
Balance Sheet Composition
Carmat S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -49.2M | -52.5M | -51.9M | -60.4M | -37.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 0 | 0 | 0 | -9.4M | -18.6M |
Operating Cash Flow | -43.5M | -59.4M | -52.9M | -78.0M | -53.0M |
Investing Activities | |||||
Capital Expenditures | -1.5M | -5.0M | -1.7M | -1.8M | -2.3M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | -72.0K |
Investment Sales | - | - | - | 13.0K | - |
Investing Cash Flow | -1.4M | -4.9M | -2.0M | -1.8M | -2.4M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | 10.0M | 20.0M |
Debt Repayment | -831.0K | -1.1M | -481.0K | -255.0K | - |
Financing Cash Flow | 41.4M | 15.0M | 68.6M | 65.1M | 25.8M |
Free Cash Flow | -44.8M | -58.5M | -56.1M | -61.9M | -45.4M |
Net Change in Cash | -3.5M | -49.3M | 13.7M | -14.6M | -29.6M |
Cash Flow Trend
Carmat S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-0.11
Forward P/E
-0.05
Price to Sales
1.09
PEG Ratio
-0.05
Profitability Ratios
Profit Margin
-336.56%
Operating Margin
-644.75%
Return on Equity
100.52%
Return on Assets
-64.45%
Financial Health
Current Ratio
1.68
Debt to Equity
-1.13
Beta
1.37
Per Share Data
EPS (TTM)
€-1.15
Book Value per Share
€-0.81
Revenue per Share
€0.16
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alcar | 8.6M | -0.11 | - | 100.52% | -336.56% | -1.13 |
Guerbet S.A | 341.6M | 15.28 | 0.62 | 3.50% | 1.89% | 100.91 |
Eurobio Scientific | 253.4M | 64.87 | 1.42 | 2.26% | 2.58% | 5.46 |
Median Technologies | 87.8M | -1.75 | - | 74.31% | -109.93% | -0.98 |
Affluent Medical | 59.2M | -3.85 | 1.83 | -48.69% | -275.50% | 0.54 |
Novacyt S.A | 34.8M | -0.80 | 0.70 | -57.28% | -212.73% | 24.81 |
Financial data is updated regularly. All figures are in the company's reporting currency.